Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Paragon 28's Shares Rise After Launch of Phantom Fibula Nail System
by Zacks Equity Research
FNA unveils Phantom Fibula Nail System, a less invasive, next-gen solution for ankle fractures, offering enhanced precision, stability and better patient outcomes.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
by Zacks Equity Research
ABT delivers a strong underlying base business performance in the third quarter of 2024.
Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan
by Zacks Equity Research
CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
by Zacks Equity Research
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
by Zacks Equity Research
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
GE HealthCare's Shares Rise After the Launch of Versana Premier
by Zacks Equity Research
GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
All You Need to Know About Addus HomeCare (ADUS) Rating Upgrade to Buy
by Zacks Equity Research
Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare
by Zacks Equity Research
Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.
Addus HomeCare (ADUS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 12.50% and 1.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Encompass Health (EHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Compared to Estimates, Addus HomeCare (ADUS) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?